文献速递炎症性肠病

炎症性肠病患者接受抗TNF药物治疗期间接种带状疱疹疫苗的安全性

Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications.
PubMed 文献 · Aliment Pharmacol Ther · 2017-08-14

接种后0至42天内未发现带状疱疹病例,作者认为在该人群中共用带状疱疹疫苗相对安全。

要点

  • 59例抗TNF治疗期间接种带状疱疹疫苗者中,12例(20%)同时使用硫嘌呤。
  • 接种带状疱疹疫苗时中位年龄64.9岁,95%患者Charlson合并症指数≥2。
  • 接种后0至42天内未发现带状疱疹病例。

核心结论

  • 作者认为,对正在使用抗TNF药物的患者共用带状疱疹疫苗相对安全。
  • 本研究显著扩展了支持该人群使用带状疱疹疫苗的证据,纳入的是Charlson合并症指数较高、发生带状疱疹风险可能更高的老年患者。

研究设计与样本

  • 回顾性队列研究,纳入2001至2016年在退伍军人事务医疗系统随访的炎症性肠病患者。
  • 通过疫苗接种代码识别并在抗TNF药物治疗期间接种带状疱疹疫苗的患者,并经逐份病历回顾确认。

主要发现

  • 59例在抗TNF治疗期间接种带状疱疹疫苗者中,12例(20%)同时使用硫嘌呤。
  • 接种带状疱疹疫苗时中位年龄为64.9岁,95%患者Charlson合并症指数≥2。
  • 接种带状疱疹疫苗后42天内中位就诊次数为2次。
  • 接种后0至42天内未发现带状疱疹病例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risk of herpes zoster (HZ) is elevated in inflammatory bowel disease (IBD) patients treated with anti-TNF medications. While it is optimal to give herpes zoster vaccine prior to initiation of therapy clinical circumstances may not always allow this. AIM: To determine the safety of giving herpes zoster vaccine while patients are on anti-TNF therapy. METHODS: We conducted a retrospective cohort study involving IBD patients who were followed in the Veterans Affairs (VA) healthcare system between 2001 and 2016. Patients who received herpes zoster vaccine while on anti-TNF medication were identified through vaccination codes and confirmed through individual chart review. Our outcome of interest was development of HZ between 0 and 42 days after herpes zoster vaccine administration. RESULTS: Fifty-six thousand four hundred and seventeen patients with IBD were followed in the VA healthcare system. A total of 59 individuals were on anti-TNF medication when they were given herpes zoster vaccine, and amongst them, 12 (20%) were also taking a thiopurine. Median age at the time of herpes zoster vaccine was 64.9 years and 95% of patients had a Charlson Comorbidity Index of ≥2. Median number of encounters within 42 days after receiving herpes zoster vaccine was two. No case of HZ was found within 0-42 days of HZV administration. CONCLUSION: Our data suggest that co-administering the herpes zoster vaccine to patients who are taking anti-TNF medications is relatively safe. This study significantly expands the evidence supporting the use of herpes zoster vaccine in this population, having included an elderly group of patients with a high Charlson Comorbidity Index who are likely at a much higher risk of developing HZ.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Khan N, Shah Y, Trivedi C, et al. Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications. Aliment Pharmacol Ther. 2017. PMID: 28805309. doi:10.1111/apt.14257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。